Last reviewed · How we verify
PF-00868554
At a glance
| Generic name | PF-00868554 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients (PHASE1)
- Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects (PHASE2)
- Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus. (PHASE1)
- Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554 (PHASE1)
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection (PHASE2)
- Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance (PHASE1)
- Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol) (PHASE1)
- A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-00868554 CI brief — competitive landscape report
- PF-00868554 updates RSS · CI watch RSS
- Pfizer portfolio CI